Oncoleader reposted this
POSITIVE CLINICAL DATA FOR CAR-T THERAPY: My 3-Minute Breakdown ARCELLX just released a sneak preview of their most recent clinical data that has many people in the industry buzzing. The data come from a phase II trial of 58 patients with relapsed/refractory multiple myeloma that were treated with their BCMA-targeting "ddCAR-T cell" platform called anito-cel. What exactly are ddCAR-T cells? What does the data show? Why is it important? Check out my 3-minute breakdown to get the full scoop! --- ❗❗P.S. if you like this kind of content (oncology news delivered in video format), send me a direct message, I have a very special offer for you!
This is great
Jeffrey C. Martin, Ph.D.! If Arcellx can prove their platform works better than existing BCMA-targeted CAR-Ts (Carvykti or Abecma), they’ll grab a huge slice of this growing market.
Insightful! ASH is heating up to be an exciting summit. Jeffrey C. Martin, Ph.D.
Stealth Startup
1mohttps://www.businesswire.com/news/home/20241104656062/en/Arcellx-to-Present-Clinical-Data-for-Its-Phase-1-and-iMMagine-1-Studies-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma-at-the-66th-ASH-Annual-Meeting-and-Exposition-and-Announces-Progress-in-iMMagine-3-Study